Trial Profile
A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Dose-escalation, Single Centre Study to Assess the Safety and Efficacy of AVX001 when Administered Topically Once Daily in Patients with mild to moderate plaque psoriasis vulgaris in doses of 3% and 5% ointment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2020
Price :
$35
*
At a glance
- Drugs AVX 001 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Avexxin; Coegin Pharma
- 11 Jul 2015 Status changed from recruiting to completed as reported by EudraCT record.
- 14 Jan 2015 New trial record